Polyrizon Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Polyrizon Ltd. (Nasdaq: PLRZ) develops innovative medical device hydrogels delivered as nasal sprays that form protective barriers in the nasal cavity against viruses, allergens and airborne pathogens; its proprietary Capture and Contain (C&C) platform creates a bio-adhesive hydrogel shield to trap and neutralize particulates including allergens, certain COVID-19 variants and influenza; the Trap and Target (T&T) platform enables intranasal delivery of active pharmaceutical ingredients with extended release for applications such as central nervous system therapies, opioid overdose treatments and allergic rhinitis; lead product candidates include PL-14, a nasal allergy blocker that provides a moisturizing barrier to capture airborne allergens; PL-15, a COVID-19 blocker; and PL-16, an influenza blocker. The company operates in the biotechnology sector targeting respiratory protection and intranasal drug delivery markets for allergy sufferers, viral prevention and therapeutic applications, with primary activities conducted in Israel. Polyrizon Ltd., founded in 2005, maintains headquarters at 5 Ha-Tidhar Street, Ra'anana, Israel. Recent developments include a $4.2 million initial public offering completed in October 2024, followed by a $17.0 million private placement closed in April 2025 comprising ordinary shares, pre-funded units and warrants to support general corporate purposes, working capital, research and development; strategic partnerships with SciSparc for exclusive rights to the SCI-160 platform in non-opioid pain treatments and with NurExone Biologic for intranasal delivery of exosome-based therapies targeting spinal cord injuries and potential neurological applications; a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S. to produce clinical trial materials for PL-14 compliant with U.S. and European standards; and successful completion of a key manufacturing upscaling milestone for PL-14 in December 2025, validating larger-scale production for a clinical trial expected to commence in 2026 to evaluate safety and efficacy as a non-pharmacological allergy solution.
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Polyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program